REPL ALERT: Securities Fraud Class Action Launched Against Replimune Group, Inc. - October 5, 2026 Deadline
Levi & Korsinsky, LLP announced a securities fraud class action filed against Replimune Group (NASDAQ: REPL) covering investors who bought shares between October 20, 2025 and April 10, 2026, with an October 5, 2026 lead plaintiff deadline. The complaint alleges Replimune concealed that FDA study-design concerns were unaddressed in its BLA and that it submitted an early unplanned RP1-104 analysis with only 40 patients — 10% of the planned 400-patient enrollment — making BLA rejection likely for RP1-104 and RPL-001-16.
Key figures
- Class period
- October 20, 2025 to April 10, 2026
- Planned enrollment
- 400
- Lead plaintiff deadline
- October 5, 2026
- Patients in unplanned analysis
- 40
- Unplanned analysis share of enrollment
- 10%
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.